Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuances
Ratios

Lifecore Biomedical (LFCR) Short-Term Debt repayments: 2012-2023

Historic Short-Term Debt repayments for Lifecore Biomedical (LFCR) over the last 8 years, with May 2023 value amounting to $12.2 million.

  • Lifecore Biomedical's Short-Term Debt repayments rose 22.40% to $12.2 million in Q2 2023 from the same period last year, while for May 2023 it was $64.6 million, marking a year-over-year increase of 46.54%. This contributed to the annual value of $146.7 million for FY2024, which is 168.49% up from last year.
  • Per Lifecore Biomedical's latest filing, its Short-Term Debt repayments stood at $12.2 million for Q2 2023, which was down 70.58% from $41.6 million recorded in Q1 2023.
  • In the past 5 years, Lifecore Biomedical's Short-Term Debt repayments registered a high of $95.0 million during Q1 2021, and its lowest value of $800,000 during Q4 2022.
  • In the last 3 years, Lifecore Biomedical's Short-Term Debt repayments had a median value of $12.2 million in 2023 and averaged $24.8 million.
  • In the last 5 years, Lifecore Biomedical's Short-Term Debt repayments skyrocketed by 1,033.33% in 2019 and then plummeted by 90.00% in 2022.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Short-Term Debt repayments stood at $37.0 million in 2019, then slumped by 86.49% to $5.0 million in 2020, then skyrocketed by 60.00% to $8.0 million in 2021, then plummeted by 90.00% to $800,000 in 2022, then climbed by 22.40% to $12.2 million in 2023.
  • Its last three reported values are $12.2 million in Q2 2023, $41.6 million for Q1 2023, and $800,000 during Q4 2022.